Page 96 - Read Online

Thomas et al. J Transl Genet Genom 2024;8:249-77 https://dx.doi.org/10.20517/jtgg.2024.15 Page 273

156. Ashrafi A, Akter Z, Modareszadeh P, et al. Current landscape of therapeutic resistance in lung cancer and promising strategies to
overcome resistance. Cancers 2022;14:4562. DOI PubMed PMC
157. Marin JJ, Al-Abdulla R, Lozano E, et al. Mechanisms of resistance to chemotherapy in gastric cancer. Anti Agent Med Chem
2016;16:318-34. DOI
158. Wang Q, Shen X, Chen G, Du J. Drug resistance in colorectal cancer: from mechanism to clinic. Cancers 2022;14:2928. DOI
PubMed PMC
159. Scott AK, Rafuse M, Neu CP. Mechanically induced alterations in chromatin architecture guide the balance between cell plasticity
and mechanical memory. Front Cell Dev Biol 2023;11:1084759. DOI PubMed PMC
160. Burnet FM. The Concept of immunological surveillance. Prog Exp Tumor Res 1970;13:1-27. DOI
161. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat
Immunol 2002;3:991-8. DOI PubMed
162. Penn I. Posttransplant malignancies. Transplant Proc 1999;31:1260-2. DOI PubMed
163. Sheil AG. Cancer after transplantation. World J Surg 1986;10:389-96. DOI PubMed
164. Penn I. Malignant melanoma in organ allograft recipients. Transplantation 1996;61:274-8. DOI PubMed
165. Penn I. Sarcomas in organ allograft recipients. Transplantation 1995;60:1485-91. DOI PubMed
166. Pham SM, Kormos RL, Landreneau RJ, et al. Solid tumors after heart transplantation: lethality of lung cancer. Ann Thorac Surg
1995;60:1623-6. DOI
167. Nair SS, Weil R, Dovey Z, Davis A, Tewari AK. The tumor microenvironment and immunotherapy in prostate and bladder cancer.
Urol Clin North Am 2020;47:e17-54. DOI PubMed
168. Zhong C, Li Y, Yang J, et al. Immunotherapy for hepatocellular carcinoma: current limits and prospects. Front Oncol
2021;11:589680. DOI PubMed PMC
169. Jia D, Zhou Z, Kwon OJ, et al. Stromal FOXF2 suppresses prostate cancer progression and metastasis by enhancing antitumor
immunity. Nat Commun 2022;13:6828. DOI PubMed PMC
170. Lander VE, Belle JI, Kingston NL, et al. Stromal reprogramming by FAK inhibition overcomes radiation resistance to allow for
immune priming and response to checkpoint blockade. Cancer Discov 2022;12:2774-99. DOI
171. Yang D, Duan MH, Yuan QE, et al. Suppressive stroma-immune prognostic signature impedes immunotherapy in ovarian cancer and
can be reversed by PDGFRB inhibitors. J Transl Med 2023;21:586. DOI PubMed PMC
172. Bremnes RM, Dønnem T, Al-Saad S, et al. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-
associated fibroblasts and non-small cell lung cancer. J Thorac Oncol 2011;6:209-17. DOI
173. Nishikawa H, Koyama S. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision
therapies. J Immunother Cancer 2021;9:e002591. DOI PubMed PMC
174. Lunardi S, Jamieson NB, Lim SY, et al. IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes
recruitment and correlates with poor survival. Oncotarget 2014;5:11064-80. DOI PubMed PMC
175. Vilgelm AE, Richmond A. Chemokines modulate immune surveillance in tumorigenesis, metastasis, and response to immunotherapy.
Front Immunol 2019;10:333. DOI PubMed PMC
176. Hussain S, Peng B, Cherian M, Song JW, Ahirwar DK, Ganju RK. The roles of stroma-derived chemokine in different stages of
cancer metastases. Front Immunol 2020;11:598532. DOI PubMed PMC
177. Deng J, Jiang R, Meng E, Wu H. CXCL5: a coachman to drive cancer progression. Front Oncol 2022;12:944494. DOI PubMed
PMC
178. Kraman M, Bambrough PJ, Arnold JN, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation
protein-alpha. Science 2010;330:827-30. DOI
179. Poznansky MC, Olszak IT, Foxall R, Evans RH, Luster AD, Scadden DT. Active movement of T cells away from a chemokine. Nat
Med 2000;6:543-8. DOI PubMed
180. Kryczek I, Wei S, Keller E, Liu R, Zou W. Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol
Cell Physiol 2007;292:C987-95. DOI PubMed
181. Schreiber H, Rowley DA. Cancer. Awakening immunity. Science 2010;330:761-2. DOI PubMed
182. Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and
progression. Trends Immunol 2010;31:220-7. DOI PubMed PMC
183. Shi X, Young CD, Zhou H, Wang X. Transforming growth factor-β signaling in fibrotic diseases and cancer-associated fibroblasts.
Biomolecules 2020;10:1666. DOI PubMed PMC
184. Mariathasan S, Turley SJ, Nickles D, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T
cells. Nature 2018;554:544-8. DOI
185. Zippi M, De Toma G, Minervini G, et al. Desmoplasia influenced recurrence of disease and mortality in stage III colorectal cancer
within five years after surgery and adjuvant therapy. Saudi J Gastroenterol 2017;23:39-44. DOI PubMed PMC
186. Whatcott CJ, Posner RG, Von Hoff DD, Han H. Chapter 8 desmoplasia and chemoresistance in pancreatic cancer. In: Grippo PJ,
Munshi HG, editors. Pancreatic cancer and tumor microenvironment. India: Trivandrum; 2012. Available from: https://www.ncbi.
nlm.nih.gov/books/NBK98939/ [Last accessed on 22 Jul 2024].
187. DeClerck YA. Desmoplasia: a response or a niche? Cancer Discov 2012;2:772-4. DOI